CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
CNS Disorders
Advertisement
Kazia Advances Paxalisib in Rare Seizure Disorders
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1
WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...
SciSparc Pursues FDA Orphan Drug Designation for SCI-110 in Tourette Syndrome
Tel Aviv, Israel, September 2, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. is pursuing U.S....
Praxis Precision Medicines Advances Key Regulatory Programs
BOSTON, August 6, 2026 Praxis Precision Medicines reported its second quarter 2026 financial results, highlighting continued regulatory progress for...
Advertisements
SciSparc Subsidiary NeuroThera Launches Phase IIb Trial of SCI-110 for Tourette Syndrome
TEL AVIV, Israel, Aug. 5, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. has initiated a...
Harmony Biosciences Reports Record Q2 2026 Revenue, Shares Positive BP-205 Phase 1 Data
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
MapLight Therapeutics Announces Positive Phase 2 Schizophrenia Data
SAN FRANCISCO and BOSTON, July 27, 2026 MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR clinical...
Dassault Systèmes Powers Virtual Twin Factories with AI Agents
VELIZY-VILLACOUBLAY, France, July 23, 2026 Dassault Systèmes has expanded its 3DEXPERIENCE AI-native agentic platform with the launch of three...
Apertura Joins ARPA-H Program for Rare Gene Therapies
NEW YORK, N.Y., July 23, 2026 Apertura Gene Therapy has announced its participation in a consortium selected to receive...
Advertisement
